Mindray Medical International Limited, the Shenzhen-based medical device and in-vitro diagnostic test company, announced its first quarter financial results, reporting substantial increases in revenues and profits. The results were not only ahead of last year, but they beat the numbers projected by Wall Street analysts. While releasing the details of its Q1 performance, the company also issued new guidance for the year that includes its soon-to-be-completed acquisition.  More details...

Stock Symbols: (NYSE: MR) (NSDQ: DSCP)